Lexapro and Computerised tomogram abnormal - a phase IV clinical study of FDA data

Summary:

Computerised tomogram abnormal is reported as a side effect among people who take Lexapro (escitalopram oxalate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Zometa, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Computerised tomogram abnormal when taking Lexapro. It is created by eHealthMe based on reports of 82,231 people who have side effects when taking Lexapro from the FDA, and is updated regularly.

What is Lexapro?

Lexapro has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 91,458 Lexapro users. Check the latest studies of Lexapro.

What is Computerised tomogram abnormal?

Computerised tomogram abnormal is found to be associated with 663 drugs and 650 conditions by eHealthMe. Check the latest studies of Computerised tomogram abnormal.

On Nov, 23, 2025

82,231 people reported to have side effects when taking Lexapro.
Among them, 50 people (0.06%) have Computerised tomogram abnormal.

Could Lexapro cause Computerised tomogram abnormal?

Among these 50 people:

How long have people been on Lexapro when they have Computerised tomogram abnormal? *

What is the gender of people who have Computerised tomogram abnormal when taking Lexapro? *

female: 51.02 %
male: 48.98 %

What is the age of people who have Computerised tomogram abnormal when taking Lexapro? *

What are other drugs people take besides Lexapro? *

What are other side effects people have besides Computerised tomogram abnormal? *

Fatigue (feeling of tiredness): 32 people, 64.00%
Pain: 24 people, 48.00%
Back Pain: 22 people, 44.00%
Memory Loss: 22 people, 44.00%
Pain In Extremity: 20 people, 40.00%
Sleep Disorder: 20 people, 40.00%
Bone Disorder: 19 people, 38.00%
Joint Pain: 19 people, 38.00%
Infection: 18 people, 36.00%
White Blood Cell Count Decreased: 17 people, 34.00%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 13 people, 26.00%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 10 people, 20.00%
Prostate Cancer Metastatic: 10 people, 20.00%
Sleep Disorder: 10 people, 20.00%
Pain: 10 people, 20.00%
Neoplasm Malignant (cancer tumour): 10 people, 20.00%
Tremor (trembling or shaking movements in one or more parts of your body): 6 people, 12.00%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 6 people, 12.00%
Hypersensitivity: 6 people, 12.00%
Muscle Spasms (muscle contraction): 6 people, 12.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lexapro and have Computerised tomogram abnormal?

- Check whether Computerised tomogram abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lexapro:

Lexapro (91,458 reports)

Browse all side effects of Lexapro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Computerised tomogram abnormal:

Computerised tomogram abnormal (663 drugs)

Browse all the conditions that are associated with Computerised tomogram abnormal:

Computerised tomogram abnormal (650 conditions)

Drugs similar to Lexapro and Computerised tomogram abnormal :

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Lexapro) and Lexapro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.